Home/Top Cited Articles (Published 2021 – 2022)

Top Cited Articles (Published 2021 – 2022)

Acceptance rate:
23%
Impact Factor (JCR):
12.485
IF rank (Oncology):
25/245
IF rank (Immunology):
79/162
Citescore:
14.3
Total content views:
1.12 million
More journal metrics
How we get these metrics
*median number of days
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events Targeting immunogenic cancer cell death by photodynamic therapy: past, present and future Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometrial cancer: interim results from GARNET - a phase I, single-arm study Neoadjuvant programmed cell death 1 blockade combined with chemotherapy for resectable esophageal squamous cell carcinoma STING agonist loaded lipid nanoparticles overcome anti-PD-1 resistance in melanoma lung metastasis via NK cell activation Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer Optimizing therapeutic outcomes of immune checkpoint blockade by a microbial tryptophan metabolite Acute kidney injury in patients treated with immune checkpoint inhibitors Gut microbiome is associated with the clinical response to anti-PD-1 based immunotherapy in hepatobiliary cancers Multicenter, single-arm, phase II trial of camrelizumab and chemotherapy as neoadjuvant treatment for locally advanced esophageal squamous cell carcinoma
Mechanisms of regulatory T cell infiltration in tumors: implications for innovative immune precision therapies Extracellular HMGB1 blockade inhibits tumor growth through profoundly remodeling immune microenvironment and enhances checkpoint inhibitor-based immunotherapy Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy Tumor-associated macrophages: potential therapeutic strategies and future prospects in cancer Adoptive cellular therapy in solid tumor malignancies: review of the literature and challenges ahead Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors Off-the-shelf V delta 1 gamma delta T cells engineered with glypican-3 (GPC-3)-specific chimeric antigen receptor (CAR) and soluble IL-15 display robust antitumor efficacy against hepatocellular carcinoma COVID-19 in immunocompromised populations: implications for prognosis and repurposing of immunotherapies Regorafenib enhances antitumor immunity via inhibition of p38 kinase/Creb1/Klf4 axis in tumor-associated macrophages Clinical activity of durvalumab for patients with advanced mismatch repair-deficient and repair-proficient endometrial cancer. A nonrandomized phase 2 clinical trial